SalvaRx Group

SalvaRx Group operates as a specialized drug discovery and development company, concentrating its efforts on novel cancer immunotherapies and related oncology areas. The firm employs a virtual drug development model, strategically investing in promising therapeutic candidates and lending its expertise to their progression through clinical stages and eventual commercialization. This approach enables a focused and efficient advancement of innovative treatments.

The company was established in 2015 by Drs. Ian Walters and Rob Kramer. Both founders previously held significant roles as drug developers at Bristol-Myers Squibb, where they built substantial experience championing immune-oncology and guiding the development of relevant therapeutics. Their foundational insight centered on leveraging a targeted investment strategy to accelerate critical advancements within the burgeoning field of cancer immunotherapy.

SalvaRx Group’s efforts are directed towards ultimately benefiting patients by bringing new, effective cancer immunotherapies to market. The company’s vision is to identify and strategically advance pharmaceutical products, particularly in immune-oncology, through the development pipeline. It aims to contribute significantly to innovation in cancer treatment, striving to improve patient outcomes through its dedicated development and investment framework.